While BACE1-mediated and Aβ-mediated neural networks appear different [59], combining an mGluR1-PAM with an optimal dose of BACE1 inhibitory drugs will likely provide a complementary way to treat AD patients. Here, BACE1 is linked to Alzheimer disease.